Written and sourced by Vincent Wesley Couey, RxGrab founder. Updated .
As an Amazon Associate I earn from qualifying purchases.
These aren't obscure specialty drugs. They're medications taken by millions of Americans every day for common conditions - diabetes, blood clots, arthritis, high cholesterol. The retail prices are shocking, but so are the available discounts that most patients never learn about. For a comprehensive approach to paying less, start with our guide to cheap prescriptions.
The scale of the problem is staggering. Americans spend over $400 billion on prescription drugs annually - more per capita than any other country. The 10 drugs on this list alone account for tens of billions in annual U.S. spending. Yet for each one, there's a pathway to paying dramatically less. Most patients just never hear about it from their doctor or pharmacist.
Used for: Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis
Humira was the best-selling drug in the world for 20 years, generating over $200 billion in lifetime revenue for AbbVie. Biosimilars finally arrived in 2023 - including Hadlima, Hyrimoz, and Cyltezo - at 55-85% lower cost. If you're still on brand Humira, ask your doctor about switching to a biosimilar.
Savings options: AbbVie's Complete savings card ($5/month with insurance), biosimilars ($1,000-$3,000/month), myAbbVie Assist PAP (free for qualifying patients).
Potential savings: Switching from brand Humira to a biosimilar saves $4,200-$6,200/month - or $50,400-$74,400 per year.
Used for: Type 2 diabetes (Ozempic), weight management (Wegovy)
The most talked-about drug in America. We wrote an entire guide: Ozempic cost without insurance.
Savings options: Novo Nordisk savings card (as little as $25/month with qualifying commercial insurance, maximum savings $100/month), NovoCare self-pay price ($349/month for Ozempic 0.25 mg, 0.5 mg or 1 mg and $499/month for 2 mg, as of May 2026), PAP (free for low-income uninsured patients).
Potential savings: The NovoCare self-pay price of $349/month on most Ozempic doses is far below the brand list price.
Used for: Blood clot prevention, atrial fibrillation, DVT/PE treatment
One of the most prescribed blood thinners. No generic is available, and generic apixaban cannot launch in the U.S. before April 1, 2028. Eliquis was among the first 10 drugs in Medicare price negotiation, and its negotiated Medicare price of $231 for a 30-day supply took effect on January 1, 2026.
Savings options: BMS/Pfizer co-pay card ($10/month with insurance), Pfizer RxPathways PAP (free for those who qualify; read the program's own page).
Potential savings: Manufacturer copay card drops out-of-pocket from $620 to $10/month - a $7,320/year reduction.
Used for: Blood clot prevention, AFib, DVT/PE
Direct competitor to Eliquis. Generic rivaroxaban is available in the 2.5 mg strength (launched March 2025); the higher strengths remain brand-only.
Savings options: J&J Xarelto savings program ($10/month with insurance), PAP (free for those who qualify; read the program's own page).
Used for: Type 2 diabetes, heart failure
SGLT2 inhibitor with proven cardiovascular benefits. No generic is available as of October 2026. Jardiance's negotiated Medicare price of $197 for a 30-day supply took effect on January 1, 2026.
Savings options: Boehringer Ingelheim Jardiance savings card (with commercial insurance), BI Cares Foundation PAP (free for eligible patients).
Used for: Type 2 diabetes
Another GLP-1 receptor agonist. Similar efficacy to Ozempic for diabetes management.
Savings options: Lilly savings card ($25/month with insurance), Lilly Cares PAP (free).
Used for: Heart failure
Significantly reduces hospitalization and death from heart failure. AB-rated generic sacubitril/valsartan launched in the U.S. in July 2025. Entresto is another drug selected for Medicare price negotiation.
Savings options: Novartis co-pay card ($10/month with insurance), Novartis PAP (free).
Used for: Eczema, asthma, nasal polyps
Biologic for moderate-to-severe atopic dermatitis. One of the fastest-growing drugs by revenue.
Savings options: Dupixent MyWay copay card ($0 with qualifying insurance), Sanofi PAP (free).
Used for: Psoriasis, psoriatic arthritis, Crohn's disease
IL-23 inhibitor biologic. Administered as injection every 3 months (maintenance).
Savings options: AbbVie Complete savings ($0-$5/dose with insurance), myAbbVie Assist PAP (free).
Used for: Type 1 and Type 2 diabetes
The price of insulin has been a national scandal. Recent legislation (Inflation Reduction Act) capped Medicare insulin copays at $35/month. Eli Lilly capped all insulin at $35/month. Walmart's ReliOn brand is $25/vial.
Savings options: $35/month cap (Lilly, Medicare), Walmart ReliOn ($25/vial), manufacturer PAPs (free), state insulin safety net programs. Lilly, Novo Nordisk and Sanofi each publish their own $35 terms, exclusions and expiry dates, read 26 October 2026, in our insulin cash price guide.
The gap between manufacturing cost and retail price reveals the true scale of pharmaceutical markups:
| Drug | Estimated Mfg. Cost | U.S. Retail Price | Markup |
|---|---|---|---|
| Eliquis (30-day) | $2-$5 | $620 | 12,400-31,000% |
| Insulin (vial) | $2-$6 | $300+ | 5,000-15,000% |
| Jardiance (30-day) | $1-$3 | $580 | 19,300-58,000% |
| Xarelto (30-day) | $3-$7 | $580 | 8,300-19,300% |
These manufacturing cost estimates come from academic analyses and generic drug pricing in other countries. They don't account for R&D, clinical trials, or marketing - costs the pharmaceutical companies cite to justify pricing. But the markups explain why generics can enter the market at 80-90% discounts and still be profitable: the manufacturing itself is cheap.
This is also why Cost Plus Drugs can offer transparent pricing on generics. When the raw ingredient cost for a 90-day supply is $1.50, a 15% markup plus standard shipping (from $5.25) still yields a sub-$7 price. The traditional pharmacy supply chain adds hundreds of percentage points in margin between manufacturer and patient.
Regardless of which expensive drug you take, follow this hierarchy:
For the science behind these medications and how they compare to non-prescription alternatives, Health Britannica covers evidence-based chronic disease management.
PAPs are the most underused savings tool in American healthcare. Nearly every major pharmaceutical company operates one, and they provide free medication to patients who qualify. Here's how to navigate the process:
The approval rates are higher than most people expect. Manufacturers want patients on their drugs - it builds loyalty and generates data. For our detailed walkthrough, see the complete PAP guide.
Several blockbuster drugs have lost or are losing patent protection, which brings generic competition and massive price drops:
| Drug | Expected Generic | Expected Price Drop |
|---|---|---|
| Eliquis | April 2028 at the earliest | 80-90% |
| Xarelto | 2.5 mg launched March 2025; other strengths pending | 80-90% |
| Jardiance | Not yet scheduled | 80-90% |
| Entresto | Launched July 2025 | 70-85% |
| Ozempic (semaglutide) | 2030s | 80-90% |
When a drug goes generic, it typically becomes available on Walmart's $4 list or Cost Plus Drugs within months. We'll update our generic vs. brand guide as these launch.
The 2022 Inflation Reduction Act introduced the most significant drug pricing reforms in decades. Here's what matters for patients on expensive drugs:
These changes primarily benefit Medicare patients. If you're under 65 with private insurance, the direct impact is limited - but the competitive pressure is pushing some manufacturers to extend savings programs to all patients.
The U.S. is the only major country that doesn't negotiate drug prices at a national level (though under the Inflation Reduction Act, Medicare's first negotiated prices took effect on January 1, 2026). Drug companies set prices based on what the market will bear, and insurance/PBM middlemen add costs. The same drug often costs 2-10x more in the U.S. than in Canada or Europe.
A biosimilar is the biologic equivalent of a generic drug. Biologics (like Humira, Ozempic) are made from living cells and are more complex than traditional chemical drugs. Biosimilars must demonstrate they're highly similar to the original biologic with no clinically meaningful differences. They're typically 55-85% cheaper than the brand.
No. Federal law prohibits Medicare patients from using manufacturer copay cards or coupons. However, the Inflation Reduction Act capped Medicare Part D out-of-pocket costs at $2,000 for 2025, indexed to $2,100 for 2026, which helps with expensive drugs. Medicare patients should also check manufacturer PAPs, which some companies offer separately for Medicare enrollees.
Canadian pharmacies dispensing Health Canada-approved medications are subject to rigorous safety standards comparable to the U.S. The FDA has historically discouraged individual importation, but enforcement against personal-use quantities (90-day supply or less) is minimal. The risk is buying from illegitimate online pharmacies that claim to be Canadian but ship from other countries. Stick to CIPA-verified (Canadian International Pharmacy Association) pharmacies.
If you've exhausted copay cards and PAPs, ask your doctor about therapeutic alternatives - there may be a cheaper drug in the same class. Hospital and community health center pharmacies sometimes offer additional discounts. State pharmaceutical assistance programs exist in many states. As a last resort, organizations like the Patient Access Network Foundation and HealthWell Foundation provide copay assistance grants.
Free. The download link appears right after you sign up. Price alerts are not live yet; we will only email when they are.
Prescription prices in the United States are set through a documented chain of list prices, pharmacy benefit contracts and federal programs, and the sources below are the primary public records of how that chain works. They are linked so a reader can check a claim here without taking this page's word for it.
This page describes how prescription pricing and discount programs work. It is not medical advice, and what a given person pays depends on their own plan, pharmacy and prescriber.